Integra Lifesciences Affirms FY2026 EPS and Sales Guidance
Integra affirmed FY2026 adjusted EPS guidance of $2.30–$2.40 and sales guidance of $1.634 billion–$1.654 billion. The supplied estimates are $2.42 and $1.661 billion, respectively.
Integra Lifesciences (NASDAQ: IART) reaffirmed its FY2026 adjusted EPS outlook at $2.30-$2.40, compared with the analyst estimate of $2.42. The company also maintained its FY2026 sales outlook at $1.634 billion-$1.654 billion, versus the estimate of $1.661 billion.